medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 5

<< Back Next >>

Ann Hepatol 2013; 12 (5)

Coagulation abnormalities in the cirrhotic patient

Muciño-Bermejo J, Carrillo-Esper R, Uribe M, Méndez-Sánchez N

Language: English
References: 63
Page: 713-724
PDF size: 149.40 Kb.


ABSTRACT

The clotting process is a dynamic array of multiple processes which can be described in four phases: platelet plug initiation and formation, clotting process propagation by the coagulation cascade, clotting termination by antithrombotic mechanisms and clot removal by fibrinolysis. The liver plays a central role in each of these phases of clotting process, as it synthesizes the majority of coagulation factors and proteins involved in fibrinolysis as well as thrombopoeitin, which is responsible for platelet production from megakaryocytes. Many pathological processes associated with cirrhosis, such as portal hypertension and endothelial dysfunction, as well as co-morbid conditions, may also alter the coagulation process. Consequently, patients with liver disease have a disturbed balance of procoagulant and anti-coagulant factors which deviates from the normal coagulation cascade. This situation poses an additional problem in the diagnostic and therapeutic approach to this group of patients, since traditional coagulation test may not be reliable for assessing bleeding or thrombotic risk and traditional transfusional strategies may not be applicable in cirrhotic patients. In this article, we review the pathophysiological bases of coagulation abnormalities, in cirrhotic patients, the diagnostic therapeutic strategies to be followed and its impact on the clinical outcome in the cirrhotic patient.


REFERENCES

  1. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A, et al. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. Hepatology 2006; 44: 1039-46.

  2. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116: 878-875.

  3. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-56.

  4. Shah NL, Northup PG, Caldwell SH. A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. Ann Hepatol 2012; 11(5): 686-90.

  5. Monroe DM, Hoffman M. The coagulation cascade in cirrhosis. Clin Liver Dis 2009; 13: 1-9.

  6. Goulis J, Chau TN, Jordan S, Mehta AB, Watkinson A, Rolles K, Burroughs AK. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia are restored after orthotopic liver transplantation. Gut 1999; 44: 754-8.

  7. Kajihara M, Okazaki Y, Kato S, Ishii H, Kawakami Y, Ikeda Y, Kuwana M. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 2007; 22: 112.

  8. Hugenholtz GG, Porte RJ, Lisman T. The platelet and platelet function testing in liver. Disease Clin Liver Dis 2009; 13: 11-20.

  9. Thomas DP, Ream VJ, Stuart PK. Platelet aggregation in patients with Laennec’s cirrhosis of the liver. N Engl J Med 1967; 276: 1344-8.

  10. Witters P, Freson K, Verslype C, Peerlinck K, Hoylaerts M, Nevens F, Van Geet C, et al. Review article: blood platelet number and function in chronic liver disease and cirrhosis. Aliment Pharmacol Ther 2008; 27: 1017-29.

  11. Moiny G, Thirion A, Deby C. Bilirubin induces platelet aggregation. Thromb Res 1990; 59: 413-6.

  12. Maurer HM, J Caul, WE Laupus Bilirubin-induced platelet staining, aggregation, and adenine nucleotide release. Pediatric Research 1970: 4; 465-465.

  13. Baele G, Rasquin K, Barbier F. Coagulant, fibrinolytic, and aggregating activity in ascitic fluid. Am J Gastroenterol 1986; 81: 440-3.

  14. Violi F, Leo R, Vezza E, Basili S, Cordova C, Balsano F. Bleeding time in patients with cirrhosis: relation with degree of liver failure and clotting abnormalities. CALC Group. Coagulation Abnormalities in Cirrhosis Study Group. J Hepatol 1994; 20: 531-6.

  15. Tripodi A, Primignani M, Chantarangkul V, Clerici M, Dell’Era A, Fabris F, Salerno F, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44: 440-5.

  16. Ng VL. Liver disease, coagulation testing, and hemostasis. Clin Lab Med 2009; 29: 265-82.

  17. Kowdley KV, Emond MJ, Sadowski JA, Kaplan MM. Plasma vitamin K1 level is decreased in primary biliary cirrhosis. Am J Gastroenterol 1997; 92: 2059-61.

  18. Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost 2008; 34: 772-8.

  19. Wion K, Kelly D, Summerfield JA, Tuddenham EG, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-9.

  20. Shovlin CL, Angus G, Manning RA, Okoli GN, Govani FS, Elderfield K, Birdsey GM, et al. Endothelial cell processing and alternatively spliced transcripts of factor VIII: potential implications for coagulation cascades and pulmonary hypertension. PLoS ONE 2010; 5: e9154.

  21. Hollestelle MJ, Thinnes T, Crain K, Stiko A, Kruijt JK, van Berkel TJ, Loskutoff DJ. Tissue distribution of factor VIII gene expression in vivo-a closer look. Thromb Haemost 2001; 86: 855-61.

  22. Wagner DD. Cell biology of von Willebrand factor. Annu Rev Cell Biol 1990; 6: 217-46.

  23. De Meyer SF, Deckmyn H, Vanhoorelbeke K. Von Willebrand factor to the rescue. Blood 2009; 113: 5049-507.

  24. Smalberg JH, Leebeek FW. Superimposed coagulopathic conditions in cirrhosis: infection and endogenous heparinoids, renal failure, and endothelial dysfunction. Clin Liver Dis 2009; 13: 33-42.

  25. Zambruni A, Thalheimer U, Coppell J, Riddell A, Mancuso A, Leandro G, Perry D, et al. Endogenous heparin-like activity detected by anti-Xa assay in infected cirrhotic and non-cirrhotic patients. Scand J Gastroenterol 2004; 39: 830-6.

  26. Ferguson JW, Helmy A, Ludlam C, Webb DJ, Hayes PC, Newby DC. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency. Thromb Res 2008; 121: 675-80.

  27. Gresele P, Binetti B, Branca G, Clerici C, Asciutti S, Morelli A, Semeraro N. TAFI deficiency in liver cirrhosis: Relation with plasma fibrinolysis and survival. Thrombosis Research 2008; 121: 763-8.

  28. Bennani-Baiti N, Daw HA. Primary hyperfibrinolysis in liver disease: a critical review. Clin Adv Hematol Oncol 2011; 9: 250-2.

  29. Ferro D, Celestini A, Violi F. Hyperfibrinolysis in liver disease. Clin Liver Dis 2009; 13: 21-31.

  30. Lippi G, Targher G, Favaloro EJ, Franchini M. Venous thromboembolism in chronic liver. Semin Thromb Hemost 2011; 37: 66-76.

  31. Ferro D, Angelico F, Caldwell SH, Violi F. Bleeding and thrombosis in cirrhotic patients: what really matters? Dig Liver Dis 2012; 44: 275-9.

  32. Grønbaek H, Johnsen SP, Jepsen P, Gislum M, Vilstrup H, Tage-Jensen U, Sørensen HT. Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: a Danish population based case-control study. BMC Gastroenterol 2008; 8: 16.

  33. Chen YH, Chen KY, Lin HC. Non-alcoholic cirrhosis and the risk of stroke: a 5-year follow-up study. Liver Int 2011; 31: 354-60.

  34. Caldwell S, Northup PG. Bleeding complication with liver biopsy: is it predictable? Clin Gastroenterol Hepatol 2010; 8: 826-9.

  35. Rodriguez-Castro KI, Simioni P, Burra P, Senzolo M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int 2012; 27: 1478-3231.

  36. Gabr MA, Bessa SS, El-Zamarani EA. Portal vein thrombosis in Egyptian patients with liver cirrhosis: role of methylenetetrahydrofolate reductase C677T gene mutation. Hepatol Res 2010; 40: 486-93.

  37. Northup PG, McMahon MM, Ruhl AP, Altschuler SE, Volk-Be dnarz A, Caldwell SH, Berg CL. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-8.

  38. García-Fuster MJ, Abdilla N, Fabiá MJ, Fernández C, Oliver V, Forner MJ. Venous thromboembolism and liver cirrhosis. Rev Esp Enferm Dig 2008; 100: 259-62.

  39. Tripodi A. Tests of coagulation in liver disease. Clin Liver Dis 2009; 13: 55-61.

  40. Dahlback B. Progress in the understanding of the protein C anticoagulant pathway. Int J Hematol 2004; 79: 109-16.

  41. Whitten CW, Greilich PE. Thromboelastography: past, present, and future. Anesthesiology 2000; 92: 1223-5.

  42. Tripodi A, Primignani M, Chantarangkul V, Viscardi Y, Dell’Era A, Fabris FM, Mannucci PM. The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. Thromb Res 2009; 124: 132-6.

  43. Chau TN, Chan YW, Patch D, Tokunaga S, Greenslade L, Burroughs AK. Thrombelastographic changes and early rebleeding in cirrhotic patients with variceal bleeding. Gut 1998; 43: 267-71.

  44. Senzolo M, Sartori MT, Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? HPB 2009; 11: 459-64.

  45. Bechmann LP, Sichau M, Wichert M, Gerken G, Kröger K, Hilgard P. Low molecular-weight heparin in patients with advanced cirrhosis. Liver Int 2011; 31: 75-82.

  46. Senzolo M, Rodriguez-Castro KI, Rossetto V, Radu C, Gavasso S, Carraro P, Zerbinati P, et al. Increased anticoagulant response to low molecular weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012; 9: 1823-9.

  47. Tsuji K, Eguchi Y, Kodama M. Postoperative hypercoagulable state followed by hyperfibrinolysis related to wound healing after hepatic resection. J Am Coll Surg 1996; 183: 230-8.

  48. Senzolo M, Burroughs AK. Hemostasis alterations in liver disease and liver transplantation. In: Kitchens G, Alving B, Kessler G (eds.). Consultative Hemostasis and Thrombosis. Philadelphia, PA: Saunders; 2007, p. 490-502.

  49. Delgado MG, Seijo S, Yepes I, Achécar L, Catalina MV, García- Criado A, Abraldes JG, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012; 10: 776-83.

  50. Maruyama H, Takahashi M, Shimada T, Yokosuka O. Emergency anticoagulation treatment for cirrhosis patients with portal vein thrombosis and acute variceal bleeding. Scand J Gastroenterol 2012; 47: 686-91.

  51. Vivarelli M, Zanello M, Zanfi C, Cucchetti A, Ravaioli M, Del Gaudio M, Cescon M, et al. Prophylaxis for venous thromboembolism after resection of hepatocellular carcinoma on cirrhosis: is it necessary? World J Gastroenterol 2010; 16: 2146-50.

  52. Villa E, Cammà C, Marietta M, Luongo M, Critelli R, Colopi S, Tata C, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 2012; 143: 1253-60.

  53. Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, Romano L, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol 2010; 44: 448-51.

  54. Argo CK, Balogun RA. Blood products, volume control, and renal support in the coagulopathy of liver disease. Clin Liver Dis 2009; 13: 73-85.

  55. Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: the effect of plasma transfusion on coagulation test results. Am J Clin Pathol 2006; 126: 1-7.

  56. Dasher K, Trotter JF. Intensive care unit management of liver-related coagulation disorders. Crit Care Clin 2012; 28: 389-98.

  57. Wong AY, Irwin MG, Hui TW, et al. Desmopressin does not decrease blood loss and transfusion requirements in patients undergoing hepatectomy. Can J Anaesth 2003; 50: 14-20.

  58. Stanca CM, Montazem AH, Lawal A, Zhang JX, Schiano TD. Intranasal desmopressin versus blood transfusion in cirrhotic patients with coagulopathy undergoing dental extraction: a randomized controlled trial. J Oral Maxillofac Surg 2010; 68: 138-43.

  59. Bosch J, Thabut D, Bendtsen F, D’Amico G, Albillos A, González Abraldes J, Fabricius S, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127: 1123-30.

  60. Bosch J, Thabut D, Albillos A, Carbonell N, Spicak J, Massard J, D’Amico G, et al. Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial. Hepatology 2008; 47: 1604-14.

  61. Lodge JP, Jonas S, Jones RM, Olausson M, Mir-Pallardo J, Soefelt S, Garcia-Valdecasas JC, et al. Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation. Liver Transpl 2005; 11: 973-79.

  62. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Denninger MH, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54: 691-7.

  63. Senzolo M, Sartori TM, Rossetto V, Burra P, Cillo U, Boccagni P, Gasparini D, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int 2012; 32: 919-27.




2020     |     www.medigraphic.com